We are live on ! Find out more
ZVRA icon

Zevra Therapeutics
ZVRA

32 hedge funds and large institutions have $13.9M invested in Zevra Therapeutics in 2019 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

5% less capital invested

Capital invested by funds: $14.6M → $13.9M (-$710K)

13% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 8

16% less funds holding

Funds holding: 38 → 32 (-6)

67% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 9

Holders
32
Holders Change
-6
Holders Change %
-15.79%
% of All Funds
0.69%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
7
Reduced
8
Closed
9
Calls
$49K
Puts
–
Net Calls
+$49K
Net Calls Change
+$84K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$1.2M
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$40.8K
3
ISB
Iowa State Bank
Iowa
+$33K
4
BlackRock
BlackRock
New York
+$29.9K
5
RFN
RDA Financial Network
Iowa
+$27.5K

Top Sellers

Rank Fund Capital Flow
1
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$1.69M
2
CI
Cowen Inc
New York
-$296K
3
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$221K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$144K
5
SIM
Spark Investment Management
New York
-$86K

ZVRA Hedge Fund Activity: Q2 2019 in Review

32 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Zevra Therapeutics (ZVRA) for Q2 2019, worth a combined $13.9M — down 4.9% from $14.6M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of ZVRA and 3 opened new positions — a net loss of 6 holders — while 8 trimmed existing stakes and 7 added.

The largest buyer was Vanguard Group, adding an estimated $1.2M. The largest seller was Alyeska Investment Group, cutting an estimated $1.69M.

  • 32 institutional investors held Zevra Therapeutics (ZVRA) as of Q2 2019, down from 38 in Q1 2019.
  • Funds reported $13.9M of Zevra Therapeutics stock for Q2 2019, down 4.9% quarter-over-quarter.
  • 3 funds opened new Zevra Therapeutics positions in Q2 2019 and 9 closed out, a net change of -6 holders.
  • The largest Zevra Therapeutics buyer in Q2 2019 was Vanguard Group, an estimated $1.2M added.
  • The largest Zevra Therapeutics seller in Q2 2019 was Alyeska Investment Group, an estimated $1.69M sold.

Based on aggregated 13F filings for Q2 2019.